• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $732 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-24 Mln

Larimar Therapeutics Inc. (LRMR) Share Price

$11.50

As on 29-Feb-2024 16:00 EST

$0.000.00%

  • Prev Close info

    $11.50

  • Day's Openinfo

    $11.49

  • Today's Highinfo

    $11.90

  • Today's Lowinfo

    $11.27

  • Today's Volumeinfo

    350,012

  • 52 Week rangeinfo

    $2.18 - 13.68

Please wait...

Larimar Therapeutics Inc. (LRMR) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Larimar Therapeutics (LRMR)
152.75 135.17 238.24 82.54 -12.34 -27.46 --
S&P BSE Sensex*
2.08 2.78 10.09 25.07 14.52 15.51 13.32
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 29-Feb-2024  |  *As on 01-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Larimar Therapeutics (LRMR)
10.17 -61.72 -49.60 60.74 -77.58 7.10 45.28
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Larimar Therapeutics Inc. (LRMR) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Larimar Therapeutics Inc. (LRMR)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Larimar Therapeutics Inc. (LRMR)

        CEO, President & Director

        Dr. Carole S. Ben-Maimon M.D.

        Secretary & CFO

        Mr. Michael Celano CPA

        Headquarters

        Bala Cynwyd, PA

        FAQs for Larimar Therapeutics Inc. (LRMR)

        The total asset value of Larimar Therapeutics Inc. (LRMR) stood at $ 111 Mln as on 30-Sep-23

        The share price of Larimar Therapeutics Inc. (LRMR) is $11.50 (NASDAQ) as of 29-Feb-2024 16:00 EST. Larimar Therapeutics Inc. (LRMR) has given a return of -12.34% in the last 3 years.

        Larimar Therapeutics Inc. (LRMR) has a market capitalisation of $ 732 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Larimar Therapeutics Inc. (LRMR) is 7.89 times as on 29-Feb-2024, a 1.65% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Larimar Therapeutics Inc. (LRMR) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Larimar Therapeutics Inc. (LRMR) and enter the required number of quantities and click on buy to purchase the shares of Larimar Therapeutics Inc. (LRMR).

        Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania. Address: Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004

        The CEO & director of Dr. Carole S. Ben-Maimon M.D.. is Larimar Therapeutics Inc. (LRMR), and CFO & Sr. VP is Mr. Michael Celano CPA.

        The promoters of Larimar Therapeutics Inc. (LRMR) have pledged 0% of the total equity as on Sep-23.

        Larimar Therapeutics Inc. (LRMR) Ratios
        Return on equity(%)
        -31.42
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Larimar Therapeutics Inc. (LRMR) was $-24 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $732.21 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-24.32 Mln
        • Cash date-information $95.59 Mln
        • Total Debt info $5.39 Mln
        • Insider's Holding 1.40%
        • Liquidity liquidity High
        • 52 Week range week-range $2.18 - 13.68
        • Shares outstanding share-outstanding 43,905,900
        • 10 Years Aggregate:

          CFO: $-400.40 Mln

          EBITDA: $-396.36 Mln

          Net Profit: $-465.46 Mln

        About The Company

        • IPO Date 19-Jun-2014
        • CEO, President & Director Dr. Carole S. Ben-Maimon M.D.
        • Secretary & CFO Mr. Michael Celano CPA
        • Listing key-listing NASDAQ: LRMR
        • Country United States
        • Headquarters headquarters Bala Cynwyd, PA
        • Website website https://www.larimartx.com
        • Business

          Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical...  trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania. Address: Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004  Read more

        share-fund-plan-icon